Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing Plans to enter Phase 2/3 Trials in early 2022 DURHAM, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) — Aerami Therapeutics, Inc. a […]
Other News
Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B […]
CARMAT Announces the Second Center Implanting Its Total Artificial Heart in the United States
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by […]
Hyperfine’s Portable MRI System Demonstrates High Accuracy for Detection of Brain Hemorrhage in Study Published in Nature Communications
First-of-its-Kind Swoop System Designed to Offer an Accessible, Affordable Option for Brain Imaging GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine Inc. today announced results of a study of the company’s FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop™, published in Nature Communications. The study, which was conducted at Yale New Haven Hospital, demonstrated high accuracy […]
Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
Evolut™ FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment DUBLIN, Aug. 24, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut™ FX TAVR system. […]
Medtronic Reports First Quarter Fiscal 2022 Financial Results
Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product Launches DUBLIN, Aug. 24, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and 19% Organic GAAP Diluted EPS […]
MFDS Greenlights VUNO Med®-DeepCARS™, AI Medical Device for Cardiac Arrest Prediction
SEOUL, South Korea, Aug. 24, 2021 /PRNewswire/ — South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO Med®–DeepCARS™, an AI medical device for cardiac arrest prediction through vital signs. VUNO Med®–DeepCARS™ is a […]
Corsano Health announces the publication of a new clinical validation study for its CardioWatch 287 in cardiac patients
Wearable devices accurately measure Heart Rate and RR Intervals in 180 cardiovascular at-risk patients BUSSUM, Netherlands, Aug. 24, 2021 /PRNewswire/ — Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring devices announced the publication of a peer-reviewed clinical trial evaluating the accuracy of Heart Rate and […]
Novocardia™ Announces Key Additions to Leadership Team Accelerating Company’s Mission & Growth
Executives Bring Decades of Multifaceted Health Care Experience that Will Enable Cardiologists to More Successfully Navigate Shifts in Cardiovascular Disease Care NEW YORK, Aug. 24, 2021 /PRNewswire/ — Novocardia, a value-based cardiovascular disease care delivery platform, today announced the appointment of several new executive team members charged with accelerating the company’s mission […]
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
XARELTO® is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, now including PAD patients post-LER XARELTO® is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia […]



